Indian Diabetes Market 2022-2028

Description

List of Tables

Indian Diabetes Diagnosis and Therapeutics Market Size, Share & Trends Analysis Report byDisease Type (Type 1 Diabetes, Type 2 Diabetes, and Gestational), by Drug Type (Oral anti-diabetic Drugs, Non-Insulin Injectable drugs, and Combination Drugs), and by Device Type (Blood Glucose Monitoring Devices, Blood Glucose Strips, Insulin devices, and Others)Forecast Period (2022-2028)

The Indian diabetes diagnosis and therapeutics market is anticipated to grow at a CAGRof 7% during the forecast period. The growth of theIndian diabetes diagnosis and therapeutics market during the forecast period can be attributed to theintegration of the healthcare sector and information technology which has led to the development of innovative products. Additionally, the presence of major players such as Merck and Sanofi ispropelling the market growth during the forecast period.

The Indian diabetes diagnosis and therapeutics market is segmented based on disease type, drug type, and device type. Based on the disease type, the market is further classified into Type 1 Diabetes, Type 2 Diabetes, and gestational. Based on drug type, the market is further segmented into oral anti-diabetic drugs, non-insulin injectable drugs, and combination drugs. Based on the device type, the market is further segregated into blood glucose monitoring devices, blood glucose strips, insulin devices, and others (lancets).Among these, theoral anti-diabetic drugssegment is projected to show lucrative growth during the forecast period owing to the high prevalence of type-2 diabetes and affordability as well as ease of use of oral-antidiabetic drugs (OAD) medication.

The major companies serving the Indian diabetes diagnosis and therapeutics market includeElli Lilly and Co., Merck & Co., Inc., Novartis International AG, Pfizer Inc., and Glenmark Pharmaceuticals Ltd.,among others. The market players are considerably contributing to the market growth by the adoption of various strategies including mergers & acquisitions, partnerships, geographical expansion,and collaborations to stay competitive in the market. For instance, in January2019, Medtronics and Eris Lifesciences launched Guardian Connect in India. Guardian Connect is a Continuous Glucose Monitoring System connected with smartphone displays for a real-time data viewing of glucose levels, without a separate hardware monitor.

Research Methodology

The market study of the Indian diabetes diagnosis and therapeutics marketis incorporated by extensive primary and secondary research conducted by the research team at OMR. Secondary research has been conducted to refine the available data to breakdown the market into various segments, and derive the total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. Our team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior, and macroeconomic factors. Numbers extracted from secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings authenticity to our reports.

Secondary Sources Include

Financial reports of companies involved in the market.
Whitepapers, research papers, and news blogs.
Company websites and their product catalog.

The report provides an in-depth analysis of the market size, andintended quality of the service preferred by consumers. The report will serve as a source for a 360-degree analysis of the market thoroughly integrating different models.

Market Segmentation

1. Indian Diabetes Diagnosis and Therapeutics Market research and analysisbyDisease Type.

2. Indian Diabetes Diagnosis and Therapeutics Market Research and Analysisby Drug Type.

3. Indian Diabetes Diagnosis and Therapeutics Market Research and Analysis by Device Type.

The Report Covers

Comprehensive research methodology of the Indian diabetes diagnosis and therapeutics market.
This report also includes a detailed and extensive market overview with key analyst insights.
An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
Analysis of regional regulations and other government policies impacting the Indian diabetes diagnosis and therapeutics market.
Insights about market determinants that are stimulating the Indian diabetes diagnosis and therapeutics market.
Detailed and extensive market segments with the regional distribution of forecasted revenues.
Extensive profiles and recent developments of market players.

Product Code: OMR2017107

Category- Pharmaceuticals

1. Report Summary

Current Industry Analysis and Growth Potential Outlook
Impact of COVID-19 on the Indian Diabetes Diagnosis and Therapeutics Market
Recovery Scenario of Indian Diabetes Diagnosis and Therapeutics Market
1.1. Research Methods and Tools
1.2. Market Breakdown
- 1.2.1. By Segments

2. Market Overview and Insights

2.1. Scope of the Report
2.2. Analyst Insight & Current Market Trends
- 2.2.1. Key Findings
- 2.2.2. Recommendations
- 2.2.3. Conclusion

3. Competitive Landscape

3.1. Key Company Analysis
3.2. Eli Lilly and Co.
- 3.2.1. Overview
- 3.2.2. Financial Analysis
- 3.2.3. SWOT Analysis
- 3.2.4. Recent Developments
3.3. Merck & Co., Inc.
- 3.3.1. Overview
- 3.3.2. Financial Analysis
- 3.3.3. SWOT Analysis
- 3.3.4. Recent Developments
3.4. Novartis International AG
- 3.4.1. Overview
- 3.4.2. Financial Analysis
- 3.4.3. SWOT Analysis
- 3.4.4. Recent Developments
3.5. Pfizer Inc.
- 3.5.1. Overview
- 3.5.2. Financial Analysis
- 3.5.3. SWOT Analysis
- 3.5.4. Recent Developments
3.6. Glenmark Pharmaceuticals Ltd.
- 3.6.1. Overview
- 3.6.2. Financial Analysis
- 3.6.3. SWOT Analysis
- 3.6.4. Recent Developments
3.7. Key Strategy Analysis
3.8. Impact of COVID-19 on Key Players

4. Market Segmentation

4.1. Indian Diabetes Diagnosis and Therapeutics Market byDisease Type
- 4.1.1. Type 1 Diabetes
- 4.1.2. Type 2 Diabetes
- 4.1.3. Gestational
4.2. Indian Diabetes Diagnosis and Therapeutics Market by Drug Type
- 4.2.1. Oral anti-diabetic Drugs
- 4.2.2. Non-Insulin Injectable drugs
- 4.2.3. Combination Drugs
4.3. Indian Diabetes Diagnosis and Therapeutics Market by Device Type
- 4.3.1. Blood Glucose Monitoring Devices
- 4.3.2. Blood Glucose Strips
- 4.3.3. Insulin devices
- 4.3.4. Others (Lancets)

5. Company Profiles

5.1. AstraZeneca Plc
5.2. Eli Lilly and Co.
5.3. GlaxoSmithKline plc
5.4. Glenmark Pharmaceuticals Ltd.
5.5. Lupin Pharmaceuticals, Inc.
5.6. Merck & Co., Inc.
5.7. Micro Labs Ltd.
5.8. Novartis International AG
5.9. Novo Nordisk A/S
5.10. Pfizer Inc.
5.11. Sanofi Aventis
5.12. Sun Pharmaceutical Industries Ltd.
5.13. USV Pvt. Ltd.